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Background and purpose: The occurrence of intermediate uveitis, which is
characterized by the presence of vitreous haze (VH), in patients with multiple
sclerosis (MS) may be a sign of coexistent inﬂammatory central nervous sys-
tem (CNS) disease activity. Using an automated algorithm to quantify VH on
optical coherence tomography (OCT) scans, the aim was to investigate
whether VH in MS patients is associated with signs of inﬂammatory CNS dis-
ease activity.
Methods: Vitreous haze was quantiﬁed on OCT macular volume scans of 290
MS patients and 85 healthy controls (HCs). The relationship between VH and
clinical, retinal OCT and magnetic resonance imaging parameters of inﬂamma-
tory disease activity was investigated using generalized estimating equations.
Results: Mean VH scores did not diﬀer between patients and HCs
(P = 0.629). Six patients (2.1%) showed values higher than the highest of the
controls by HCs. VH scores did not diﬀer between the diﬀerent disease types
or between eyes with and without a history of optic neuritis (P = 0.132). VH
was not associated with inner nuclear layer volume on OCT (P = 0.233), cere-
bral T2 lesion load on magnetic resonance imaging (P = 0.416) or the develop-
ment of new relapses (P = 0.205).
Conclusion: In this study, OCT-based automated VH estimation did not
detect increased vitreous inﬂammation in MS patients compared to HCs and
did not ﬁnd an association with CNS inﬂammatory burden.
Introduction
A link between uveitis and multiple sclerosis (MS)
exists [1]. Compared to the general population,
patients with uveitis are more likely to develop MS
[1–3]. Likewise, uveitis is more common in patients
with MS. Nevertheless, the reported prevalence of
uveitis in MS patients varies greatly, with numbers
ranging from 0.65% to 36.7% [4]. Some authors have
suggested that the occurrence of uveitis in a patient
with MS indicates inﬂammatory central nervous sys-
tem (CNS) disease activity [5,6].
Intermediate uveitis, in particular, which is charac-
terized by inﬂammation of the vitreous, is thought to
be associated with MS [2,7]. In intermediate uveitis,
blood–ocular barrier breakdown results in the accu-
mulation of protein-rich ﬂuid and inﬂammatory cells
in the vitreous which is seen clinically as vitreous haze
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(VH) [8]. VH is graded by indirect ophthalmoscopy
[9]. This method, however, has several limitations,
which in turn may contribute to the aforementioned
variability in reported prevalence data. Grading is
subjective and data are noncontinuous with a poor
sensitivity for detecting faint VH [10]. Recently, a new
algorithm has been developed for the objective quan-
tiﬁcation of VH on optical coherence tomography
(OCT) scans [11].
It was hypothesized that this algorithm could
potentially detect (subclinical) ocular inﬂammation
reﬂected in increased VH in active MS patients.
Therefore, our aim was to investigate whether patients
with MS show higher levels of VH compared to
healthy controls (HCs) and whether this VH is associ-
ated with signs of inﬂammatory CNS disease activity.
Methods
Study population and clinical evaluation
Subjects were recruited from the Amsterdam MS
Cohort [12]. All patients and HCs who had received
an OCT scan at baseline assessment were eligible for
inclusion (a total of 316 MS patients and 87 HCs).
For the purpose of this study, subjects with ocular
pathology were excluded except for patients with uvei-
tis. However, none of the subjects had symptoms
indicative of uveitis at the moment of assessment.
After excluding patients due to ocular pathology (all
non-uveitic) or poor scan quality, 290 MS patients
and 85 HCs in whom at least one eye was available
were included in this study. A subset of subjects
underwent additional OCT after 2 years of follow-up.
Clinical follow-up of at least 1 year (including the
occurence of new relapses after baseline) was available
for the majority of the cohort. The inclusion and
exclusion process is shown in Fig. 1.
Clinical assessment was performed by a trained
physician and included, amongst other things, history
taking on the use of disease modifying therapy
(DMT) and the occurrence of clinical relapses. Dis-
ease duration was deﬁned as the time from ﬁrst symp-
toms until assessment. The history of MS associated
optic neuritis (MSON) was established according to a
consensus protocol [13]. The level of disability was
assessed by certiﬁed physicians by means of the
Extended Disability Status Scale [14].
Baseline magnetic resonance imaging (MRI) data
were available for the majority of subjects (230 patients
and 63 HCs). MRI was performed on a 3 T whole body
scanner (GE Signa HDxt, Milwaukee, WI, USA) using
an eight-channel phased array head coil. The MRI pro-
tocol, acquisition settings and white matter lesion seg-
mentation have been described previously [12].
This study was approved by the medical ethics com-
mittee (protocol number 2010/336) and the scientiﬁc
research committee (protocol number CWO/10-25D)
Healthy controls, N = 87
• Age 40–60 years
Exclusion criteria
• Pregnancy
• Any (previous) neurological/psychiatric disorder
• Drug or alcohol abuse
• Family member with MS (ﬁrst or second degree of 
consanguinity)
• Signiﬁcant MRI abnormalies
Paents, N = 316
• Deﬁnite diagnosis of mulple sclerosis
• Age 18–80 years
Exclusion criteria
• Relapse or corcosteroid treatment in month prior to 
baseline assessment
• Pregnancy
• Other (previous) neurological/psychiatric disorder
• Drug or alcohol abuse
• MRI abnormalies not consistent with MS
Amsterdam MS cohort
Excluded
Non-uveic ocular pathology = 8
Poor scan quality of both eyes = 18 
Excluded
Glaucoma = 1
Poor scan quality of both eyes = 1 
Baseline assessment 
Paents N = 290
Baseline assessment 
Healthy controls N = 85
Longitudinal OCT assessment
Paents N = 164
Longitudinal OCT assessment
Healthy controls N = 39
Clinical follow-up
Paents N = 208
Figure 1 Flowchart illustrating the inclusion and exclusion of study subjects.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
2 D. CORIC ET AL.
of the VU University Medical Center. Written
informed consent was obtained from all participants.
Optical coherence tomography and VH measurement
Optical coherence tomography scans were performed
with a spectral domain OCT device (Spectralis, Heidel-
berg Engineering, Heidelberg, Germany; acquisition
software version 1.7.1.0) with acquisition settings and
segmentation as previously described (see Data S1 for
more details) [15]. Follow-up scans were acquired with
the automatic follow-up function making sure the
placement of the follow-up scans was identical to the
ﬁrst scan.
Vitreous haze measurements were calculated from
the raw images recorded by the Spectralis rather than
from the contrast-corrected, standard OCT images as
described by Keane et al. [11]. Raw images were
exported from the Heyex software (Heidelberg Engi-
neering) as VOL ﬁles. The measurement used in this
work was obtained as the ratio of the mean intensity of
all pixels of the vitreous (i.e. pixels above the segmented
inner limiting membrane) and the mean values below
the vitreous (Fig. 2). This ratio was calculated sepa-
rately for each A-scan in the B-scans and then aver-
aged. The reliability of this algorithm has recently been
validated [16].
Statistical analysis
Normality of data distribution was assessed graphically
by means of histograms. Because the distribution of
VH scores was skewed to the right, all VH scores were
log-transformed, which led to a normal distribution.
All VH scores are reported as log VH scores. Diﬀer-
ences in continuous variables between patients and
HCs were tested using a two-tailed t test (parametric)
or Mann–Whitney U test (non-parametric). Categorical
variables were compared using a chi-squared test. For
the longitudinal analyses, annualized VH change scores
were calculated. For all analyses performed on eye level
(VH and retinal layer thickness), generalized estimating
equations with an exchangeable correlation matrix were
used to correct for intra-subject inter-eye dependence.
Logistic regression analysis was used to test the predic-
tive value of baseline VH scores (mean value of both
eyes) on future relapses. All analyses were performed
using SPSS version 22.0 (IBM Corporation, Armonk,
NY, USA). Statistical signiﬁcance was set at P < 0.05.
Results
Vitreous haze scores and clinical measures
The baseline characteristics of the cohort are shown
in Table 1. Patients were slightly older compared to
HCs. As expected, the eyes of MS patients (eyes with
and without a history of MSON combined) showed
more atrophy of the macular ganglion cell–inner plexi-
form layer and peripapillary retinal nerve ﬁber layer
but a thickening of the inner nuclear layer (INL) com-
pared to HC eyes.
Vitreous haze scores were negatively associated with
age (b = 0.007, P = 0.001) and disease duration
(b = 0.009, P = 0.004) in MS patients, meaning a
higher age or longer disease duration was associated
with lower VH scores. VH scores in HCs were not asso-
ciated with age (b = 0.005, P = 0.129). In order to
account for the eﬀect of age, all subsequent analyses
were corrected for age and sex, unless otherwise stated.
Overall, VH scores (reported as log VH scores) in
MS patients ranged from 2.17 to 0.30 with a mean
VH score of 0.96 (0.41). HCs had a mean VH
score of 0.93 (0.33, range 1.76 to 0.06), which
did not diﬀer signiﬁcantly from that of the MS
patients (mean diﬀerence 0.03, P = 0.629) (Fig. 3a).
Figure 2 Algorithm used for measuring vitreous haze on OCT
scans. An optical coherence tomography B-scan of the macula is
shown. This image is optimized for viewing on the screen,
clearly rendering the retinal layers visible. The red line shows the
A-scan intensity proﬁle in RAW format of the underlying verti-
cal column in the image. Notice how the sharp peaks correspond
to the inner segment/outer segment junction and retinal pigment
epithelium – Bruch’s membrane complex. This signal was used
to calculate the ratio used in our measurement. The light blue
line with sharper peaks in the vitreous and below the retina rep-
resents the same proﬁle after contrast adjustment for visualiza-
tion. Notice how the vitreous signal is artiﬁcially increased
compared to the retinal signal.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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Relapsing–remitting MS patients showed signiﬁcantly
higher VH scores compared to primary progressive
MS patients (mean diﬀerence 0.14, P = 0.043) and
secondary progressive MS patients (mean diﬀerence
0.13, P = 0.032) when age was not taken into account.
However, after adjusting for age, these diﬀerences in
VH score between relapsing–remitting MS patients
and primary progressive MS (P = 0.201) and sec-
ondary progressive MS (P = 0.113) patients were no
longer signiﬁcant (Fig. 3b). Eyes with a history of
MSON showed the same amount of VH compared to
patient eyes without a history of optic neuritis (mean
diﬀerence 0.04, P = 0.132) (Fig. 3c).
Disease modifying therapy
Out of the 290 patients, 93 were using some form of
DMT at the time of assessment. Beta interferons
were used most often (N = 51), followed by glati-
ramer acetate (N = 12), natalizumab (N = 12), ﬁn-
golimod (N = 11), dimethyl fumarate (N = 5),
teriﬂunomide (N = 1) and azathioprine (N = 1).
20.0% of the patients had used one or more DMTs
in the past but were not on any therapy at the
moment of assessment whilst 47.9% had never used
any form of DMT. After correcting for type of MS
in addition to age and sex, patients who were on
DMT showed signiﬁcantly less VH compared to
patients who had never been on DMT (mean diﬀer-
ence 0.11, P = 0.032) (Fig. 3d).
Clinical relapses
Only a small proportion of MS patients had experi-
enced a relapse in the year prior to baseline assess-
ment (11.7%, Table 1). There was no signiﬁcant
diﬀerence in the VH score of patients who did and
patients who did not experience a relapse in the year
prior to baseline (mean diﬀerence 0.00, P = 0.867)
(Fig. 3e). Clinical follow-up was available in 208
patients. Of these patients, 14 (6.7%) had experienced
a new relapse in the year following baseline assess-
ment. Although these 14 patients did show a higher
VH score compared to those patients who remained
stable (0.80  0.43 and 0.95  0.41 respectively),
this was statistically not signiﬁcant (P = 0.159)
(Fig. 3f). VH score at baseline was not predictive of
an MS relapse in the year following baseline assess-
ment (odds ratio per 0.1 increase in VH score 1.11,
P = 0.205).
Imaging parameters
Magnetic resonance imaging of the brain was avail-
able in a subset of MS patients (N = 230). In these
patients, VH scores were not associated with cerebral
T2 weighted lesion load (b = 0.086, P = 0.416)
(Fig. 4a). Baseline macular INL thickness was avail-
able for the total cohort. Cross-sectionally, VH was
not related to macular INL thickness measured on
OCT in MS patients (b = 0.003, P = 0.855, Fig. 3b)
(Fig. 4b).
Longitudinal changes in VH score
Longitudinal OCT data were available for 164
patients and 39 HCs. On average, these subjects had
been followed up for a period of 2.19 years. During
this follow-up period, three patients experienced a
clinical episode of MSON in an eye that had not been
previously aﬀected. The aﬀected eyes of these patients
were excluded from the longitudinal analyses.









51.5 (10.1) 49.3 (8.2) 0.039





RRMS 200 (69.0%) N/a
SPMS 59 (20.3%)
PPMS 31 (10.7%)
EDSS, median [range] 3.5 [0–8.0] N/a
History of MSON
No MSON 157 (54.1%) N/a
Unilateral MSON 81 (27.9%)
Bilateral MSON 39 (13.4%)
Unknown 13 (4.5%)
Use of disease modifying therapy
Current 93 (32.1%) N/a
Past 58 (20.0%)
Never 139 (47.9%)
Relapses in year prior to assessment




77.5 (14.3) 92.2 (6.0) <0.001a
pRNFL thickness (lm),
mean (SD)
84.6 (14.4) 95.1 (7.9) <0.001a
INL thickness (lm),
mean (SD)
40.4 (3.3) 39.4 (2.9) 0.003a
Vitreous haze score,
mean (SD)
0.96 (0.41) 0.93 (0.33) 0.629a
EDSS, Expanded Disability Status Scale; HCs, healthy controls;
INL, inner nuclear layer; mGCIPL, macular ganglion cell–inner
plexiform layer; MS, multiple sclerosis; MSNON, no history of MS
associated optic neuritis; MSON, MS associated optic neuritis;
PPMS, primary progressive MS; pRNFL, peripapillary retinal nerve
ﬁber layer; RRMS, relapsing–remitting MS; SPMS, secondary pro-
gressive MS. aAdjusted for age and sex.
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Figure 3 Mean vitreous haze scores (SD) in all patients combined and HCs (a) and in the diﬀerent patient subgroups (b–f). All anal-
yses were adjusted for age and sex. The relationship between vitreous haze and use of DMT was additionally adjusted for type of MS
(disease course). DMT, disease modifying therapy; HCs, healthy controls; MS, multiple sclerosis; MSNON, no history of MS associ-
ated optic neuritis; MSON, MS associated optic neuritis; PP, primary progressive; RR, relapsing–remitting; SP, secondary progressive.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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Table 2 shows the annualized VH changes in MS
patients and HCs. MS patients showed a small but
statistically signiﬁcant decline in VH score of 0.019/
year (P = 0.006) whilst HCs showed no signiﬁcant
changes over time (0.0026/year, P = 0.852). No dif-
ference in longitudinal VH changes was found
amongst the diﬀerent subgroups. Annualized changes
in INL thickness were not related to annualized
changes in VH scores in patients (b = 0.16,
P = 0.083).
Discussion
In this study, it was postulated that MS patients
might show signs of increased ocular inﬂammation,
reﬂected in increased VH, as a sign of inﬂammatory
CNS disease activity. However, using an objective
measure to quantify VH on OCT scans, no evidence
of increased levels of VH in MS patients could be
found compared to HCs. In addition, no association
between VH and measures of CNS inﬂammation was
found.
(a) (b)
β = –0.086, P = 0.416
r = –0.075, P = 0.171 
β = 0.003, P = 0.855
r = 0.021, P = 0.639 
Figure 4 Scatter plot and ﬁtted linear regression line (with 95% conﬁdence interval) demonstrating the association between vitreous
haze and cerebral lesion load (a) and inner nuclear layer (INL) thickness (b) in MS patients. r, Pearson correlation coeﬃcient; b,
regression coeﬃcient.
Table 2 Annualized vitreous haze changes
Mean annualized vitreous haze change
score (95% conﬁdence interval) P value for subgroup analysis
MS patients, overall 0.019/year (0.031 to 0.007) Reference
Healthy controls 0.0026/year (0.028 to 0.023) 0.256
Type of MS
Relapsing–remitting MS 0.014/year (0.028 to 0.0002) Reference
Secondary progressive MS 0.021/year (0.053 to 0.011) 0.626
Primary progressive MS 0.044/year (0.081 to 0.007) 0.076
History of MSON
MSON eyes 0.016/year (0.037 to 0.005) Reference
MSNON eyes 0.021/year (0.036 to 0.006) 0.850
Use of disease modifying therapy
Current use 0.007/year (0.026 to 0.012) Reference
Past 0.027/year (0.053 to 0.0003) 0.208
Never 0.023/year (0.042 to 0.005) 0.198
Relapses in the year following baseline assessment
Yes 0.035/year (0.079 to 0.009) Reference
No 0.018/year (0.030 to 0.005) 0.604
MS, multiple sclerosis; MSNON, no history of MS associated optic neuritis; MSON, MS associated optic neuritis.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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The absence of higher VH in the MS population
might suggest that uveitis in MS might not be as com-
mon as previously thought. Studies investigating the
prevalence of uveitis in MS patients have yielded a
wide range of results [4,17]. Many of the smaller stud-
ies were performed in centers specialized in uveitis
possibly leading to selection bias and probably an
overestimation of the actual prevalence. It is notewor-
thy that the large, population based studies show the
lowest prevalence ﬁgures of ~1% [3,18–20]. In our
study, six out of 520 eyes, all in diﬀerent patients,
showed VH values that were higher than the highest
value of the HCs (prevalence 2.1%). This percentage
corresponds to the low prevalences found in the large,
population based studies. It is also possible that the
relatively long disease duration in our cohort of MS
patients contributed to the low VH values due to a
burnt-out stage of the disease. The ﬁnding of an
inverse association between disease duration and VH
score further strengthens this argument. Therefore,
there is a need for future studies with patients who
present early with a clinically isolated syndrome,
including MSON.
One diﬀerence between our study and most studies
that investigate the prevalence of uveitis is that our
OCT-based approach only considers vitreous inﬂam-
mation. It is therefore focused on detecting intermedi-
ate uveitis but may not detect other anatomically
isolated cases of uveitis, notably anterior or posterior
uveitis. However, almost all studies report intermedi-
ate uveitis to be the most common form in MS
patients [18,21,22]. One study reported posterior uvei-
tis to be the most common anatomical subtype,
although they do not provide further details and that
study was conducted prior to the release of the Stan-
dardization of Uveitis Nomenclature Working Group
guidelines for anatomical classiﬁcation [20].
Whilst this study is the ﬁrst to investigate the direct
relationship between VH and signs of inﬂammatory
CNS disease activity in MS, it expands on the associa-
tion between other aspects of uveitis and increased
CNS inﬂammatory activity is expanded. Retinal vas-
cular abnormalities have been shown to be associated
with increased MS activity. Lightman et al. reported
that optic neuritis patients with retinal vasculitis (and
vitreous cells) were more likely to subsequently
develop MS compared to optic neuritis patients with-
out [1]. Two other studies have shown a signiﬁcant
association between retinal periphlebitis and inﬂam-
matory CNS disease activity [5,6]. The evidence for
the association, however, is conﬂicting with some
studies showing no diﬀerences in MS course or prog-
nosis between patients with and without uveitis (all
types of uveitis) [20,23], and one study even ﬁnding a
favorable MS prognosis in patients with uveitis [18].
Since the patients in our cohort did not undergo a
specialist ophthalmological examination as part of
their routine assessment, it cannot be ruled out
whether some patients in our cohort may have had
another form of uveitis in which VH might be normal
(e.g. anterior or posterior uveitis). This lack of an
accompanying ophthalmological examination is an
important limitation of the study and such an exami-
nation should be included in similar studies in the
future. Yet it is argued that, since most of these
assessments are subjective, it would be better to
extend the imaging protocol to provide a more com-
prehensive objective assessment of ocular inﬂamma-
tory status. For example, the protocol could use
automated image-based measures of anterior chamber
cell count and chorioretinal lesions. The development
of such markers is a major focus of our group’s work.
Additionally, it would be beneﬁcial to have longitudi-
nal MRI data, to provide a better estimation of
inﬂammatory disease activity. Conversely, longitudinal
data on INL thickness are available. INL volume
changes are thought to reﬂect inﬂammatory disease
activity [24]. In our study, no association was found
between INL thickness and VH changes.
The ability of the algorithm to objectively quantify
the amount of VH on OCT scans is a strength of this
study. The resulting value is continuous and allows for
detection of small diﬀerences between subjects. Patients
with intermediate uveitis can sometimes present with
minimal complaints and establishing the presence clini-
cally can be challenging. Another strength of this study
is the large and heterogeneous cohort of MS patients.
The occurrence of uveitis in a patient with MS
might cause the clinician to doubt whether the
patient’s current treatment is appropriate. The fact
that no relationship between VH and measures of
CNS inﬂammation (most importantly relapses) was
found might provide support and reassurance for con-
tinuation of the already implemented treatment in an
MS patient suﬀering from intermediate uveitis, who
otherwise does not have any other clinical or radiolog-
ical sign of disease activity. This in turn might help to
avoid unnecessary switch to another form of DMT.
The present study found lower VH scores in patients
who were on DMT compared to those who had never
been on DMT, possibly suggesting VH might serve as
a biomarker for therapy eﬃcacy. Nevertheless, further
studies need to be conducted to support this claim.
In conclusion, this study found no evidence of
increased ocular inﬂammation in MS patients com-
pared to HCs when applying an automated algorithm
to objectively measure VH on OCT scans. Moreover,
there was no evidence for any association between
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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VH and signs of inﬂammatory CNS disease activity.
Although the clinical correlate of the OCT-based VH
measurement is limited to intermediate uveitis, the
ﬁndings of the present study suggest that the link
between (subclinical) uveitis and MS is less evident
than previously assumed.
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